Kuraray Medical Transfers Apheresis Business Rights To Kuwasumi Laboratories
This article was originally published in PharmAsia News
Tokyo-based Kuraray Medical agreed to transfer therapeutic apheresis device business rights to Kuwasumi Laboratories this October. The company also plans to transfer the apheresis device manufacturing business to Asahi Chemical Kuraray Medical. The original plan to transfer the whole business to Asahi Chemical was blocked by the Japan Fair Trade Commission in 2006. Kuraray said the negotiation with Asahi Chemical is still undergoing. (Click here for more - Japanese language
You may also be interested in...
A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.